Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
GlobeNewswire
· Generated $172.3 million in 1Q 2024 revenues, including $163.1 million in U.S. net product sales
· $137.5 million..
RNA interference
News and Video Search Results
News coverage
-
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
-
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)
GlobeNewswire
-
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
PR Newswire Asia
-
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
Business Wire
0 shares
1 views
You might like
RNA interference media coverage
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
Business Wire
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the..
-
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
GlobeNewswire
-
Global Antisense and RNAi Therapeutics Report 2024: A USD 34.7 Billion Predicted Market by 2034, with CAGR of 18% During 2024-2034
GlobeNewswire
-
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
GlobeNewswire
-
Global Liver Cancer Drug Market to Reach USD 7.83 Billion by 2030: Innovative treatments like oncolytic viruses and RNA interference (RNAi) have gained market traction
GlobeNewswire
Advertisement
More coverage
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
Business Wire
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the..
-
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
GlobeNewswire
-
Oligonucleotide Synthesis Market projected to reach USD 27.61 Billion by 2030, growing at a CAGR of 15.7% during the forecast period of 2023-2030 - says MarketDigits in its latest study
GlobeNewswire
-
Europe Nucleic Acid Therapeutics CDMO Market Analysis and Forecasts, 2023-2033: Increasing FDA or European Medicines Agency Approvals, Pharmaceutical Firms Becoming More Outsourcing-Oriented
GlobeNewswire
-
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024
GlobeNewswire